What is BPC-157? Research and status in the Philippines
Not yet medically reviewed. Fact-checked against the sources listed below on October 7, 2026.How we write and review
Last updated October 7, 2026
BPC-157 is a synthetic peptide, a 15 amino acid fragment of a protein first described in gastric juice. Nearly all research is in animals, human data come from a few small studies, and the US FDA found no approved product in any country. WADA bans it in sport. An FDA Philippines portal search on October 7, 2026 found no record.
Key takeaways
- BPC-157 is a lab-made peptide of 15 amino acids. Researchers in Zagreb, Croatia described its parent protein, BPC, in gastric juice in 1993.
- A 2025 systematic review found 36 studies, of which 35 were preclinical (animal or lab) and 1 was clinical. It found no clinical safety data.
- The US FDA found five small human studies and says there is "insufficient clinical safety information to characterize the safety profile" of BPC-157. It found no approved BPC-157 product in any country.
- In 2026 the US FDA proposed that BPC-157 not be added to its list of substances allowed in pharmacy compounding, citing gaps in quality, safety and evidence data. AJMC and DLA Piper reported in July 2026 that its advisory committee voted 8 to 6, with 1 abstention, to recommend adding it. The vote is non-binding, and no final FDA decision was found.
- BPC-157 is named in class S0 of the WADA Prohibited List in 2022, 2026 and 2027, which means athletes may not use it at any time.
- No FDA Philippines advisory or web page naming BPC-157 was found in a search of the FDA Philippines website on October 7, 2026.
What is BPC-157?
BPC-157 is a synthetic peptide made of 15 amino acids. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is also known as Body Protection Compound 157, PL 14736 and Bepecin.
Its story starts in Croatia. In 1993, researchers at the Department of Pharmacology of the University of Zagreb described "a new gastric juice peptide", which they named BPC. They reported that a 15 amino acid fragment of it, BPC 157, was "thought to be essential for its activity".
It is an investigational compound. The US FDA says no product containing BPC-157 is approved in any country, and it is not listed in the European, Japanese or International Pharmacopoeias. It exists as a free base and as an acetate salt, which the US FDA treats as two different active ingredients.
Why do people talk about BPC-157?
The benefits claimed for BPC-157 rest on animal and lab studies, not human trials, and it is widely promoted online.
- Online interest: a 2025 review quoted by the US FDA says that in June 2024 Google search interest in BPC-157 was at an all-time high, with "over 50 million 'BPC-157' tagged video views on both YouTube and TikTok".
- Marketing claims: the US FDA found websites of US compounding pharmacies, med spas and clinics promoting BPC-157 for gut health, ulcers, inflammation and healing of tendons, ligaments and bones.
- Sports use: a 2025 systematic review says it is increasingly used by clinicians and athletes, even though it lacks US FDA approval and is banned in professional sports.
USADA says no human clinical trials have shown that BPC-157 works for any diagnosis or treatment.
How is BPC-157 thought to work?
No one knows how BPC-157 might work in people. The US FDA says "the molecular targets for BPC-157 have not been identified and its mechanisms of action remain poorly understood."
The ideas below are proposed from animal and lab studies only:
- New blood vessels (angiogenesis): reviews link BPC-157 to pathways such as VEGFR2 and to growth of new blood vessels, along with fibroblast activity and lower inflammation.
- Nitric oxide: reviews describe effects on nitric oxide production through the Akt-eNOS pathway. In a 2026 lab study using leftover artery tissue from 12 heart bypass operations, BPC 157 relaxed the arteries mainly through a nitric oxide pathway. That study used tissue in a dish, not living people.
- Growth factors: a 2025 systematic review says it may increase growth hormone receptor expression and pathways linked to cell growth, while lowering inflammatory signals.
- Collagen: experimental studies link it to collagen production.
How long it lasts in the body is also uncertain. In rats and dogs, its half-life was under 30 minutes, and it was broken down into small fragments and amino acids. A 2026 review points out that this short half-life does not fit with effects reported to last hours to days, and says its behaviour in the human body "remains critically undercharacterized".
What does the animal research show?
Nearly all BPC-157 research is preclinical. A 2025 systematic review included 36 studies: 35 were preclinical and 1 was clinical. A 2019 review noted that most studies used small rodents and that "only a handful of research groups" had studied the peptide in depth.
| Area studied | What animal studies reported | Caveats |
|---|---|---|
| Muscle, tendon, ligament and bone injuries | Improved outcomes in preclinical models (2025 systematic review) | The review covered level IV and level V evidence only |
| Gut lesions, colonic fistulas and liver damage | In rats, BPC-157 could prevent colonic fistulas, liver lesions and gut lesions caused by different challenges (US FDA review) | No dose-response was shown, and in several studies BPC-157 was given before or with the injury |
| Kidneys, brain and spinal cord | Kidney-protective effects and protective effects in rodent models of stroke, brain disease and spinal cord injury (US FDA review) | Rodent models only |
| Toxicology | Not a mutagen in standard lab tests, and no birth defects seen in pregnant rats given it by injection (one published study, summarised by the US FDA) | The study did not cover a full reproductive cycle, and the FDA identified no cancer-risk studies |
What human evidence exists?
Very little. The US FDA's 2026 review found five clinical studies that used BPC-157. Three were small pilot studies with full published results. Two were reported only as conference abstracts.
| Study | People | Design | What was reported | Main limits |
|---|---|---|---|---|
| Phase 1 study in healthy volunteers (2002 and 2003, abstracts only) | 32 randomized, 24 given BPC-157 | Placebo-controlled, given as an enema | Headache and flatulence were the most common side effects, with no obvious difference from placebo | Only conference abstracts exist |
| Ulcerative colitis trial (2005, abstract only) | 53 randomized, 46 finished | Randomized, double-blind, placebo-controlled, enema for 2 weeks | Disease activity score fell 3.2 points with BPC-157 and 1.6 with placebo, an estimated difference of 1.6 points (95% CI -4.84 to 1.62) | The US FDA calls the data "inadequate" to support use in ulcerative colitis |
| Knee pain chart review (2021) | 16 reached by phone | Retrospective, no control group | 11 of 12 who had BPC 157 alone reported significant improvement in knee pain | A 2026 review says it had significant methodological flaws and no controls |
| Interstitial cystitis pilot (2024) | 12 women | Uncontrolled, single procedure | 10 of 12 reported complete resolution of symptoms on a questionnaire | No comparison group |
| Intravenous infusion pilot (2025) | 2 adults who had used BPC-157 before | Uncontrolled | No measurable effect on tested heart, liver, kidney, thyroid or blood sugar markers. The authors reported no adverse effects | Two people only. The authors say more studies are needed to confirm safety |
Some points to keep in mind:
- A 2025 systematic review read the same knee pain study differently: it describes 7 of 12 patients reporting relief for more than 6 months.
- All three published pilot studies have the same first author and appeared in the same journal, Alternative Therapies in Health and Medicine.
- A 2026 review describes the three pilots as uncontrolled, and notes that none used standardized pharmaceutical preparations.
- The US FDA found no human studies of BPC-157 taken by mouth, injected under the skin, sprayed in the nose or applied to the skin.
Are there clinical trials of BPC-157 underway?
A few trials are registered on ClinicalTrials.gov, but none has posted results.
| Trial | Phase | People | Status (as listed) |
|---|---|---|---|
| NCT02637284, healthy volunteers in Mexico, registered 2015 | Phase 1 | 42 (estimated) | Unknown. Last updated December 2015, no results posted |
| NCT07437547, acute hamstring strain, sites in China | Phase 2, randomized, placebo-controlled | 120 (estimated) | Recruiting since February 2, 2026. Estimated primary completion February 14, 2027 |
| NCT07803250, recovery after rotator cuff repair, United States | Phase 1, randomized, compared with no treatment | 30 (estimated) | Not yet recruiting. Estimated start January 1, 2027 |
A 2026 review says BPC-157 has "no completed Phase II clinical trial". No phase 3 trial was found on ClinicalTrials.gov (October 7, 2026).
Why might animal results not carry over to people?
Positive results in rats do not show that a substance works in people. For BPC-157, the sources point to specific gaps:
- No dose-response: in the rat studies the US FDA reviewed, a dose-response relationship was not established.
- Unknown target: the molecular targets have not been identified, which makes it hard to judge whether the effects are biologically plausible.
- Timing: in several rat studies BPC-157 was given before or at the same time as the injury. The US FDA says it remains unknown whether it would help once an injury is established.
- Routes not studied: the US FDA found no human studies of BPC-157 taken by mouth, injected under the skin, used in the nose or applied to the skin.
- Few research groups: a 2019 review notes that only a handful of research groups have studied it in depth.
- Weak human studies: a 2026 scoping review of six peptides, including BPC-157, found that human studies were "limited to a handful of investigations, most lacking robust controls or rigorous study designs".
The same 2026 review concludes that claimed benefits for musculoskeletal recovery "remain unsubstantiated by current human trials", and that these peptides should not currently be advised as a replacement for, or an addition to, standard orthopaedic care. A 2026 Sports Medicine review also discusses the placebo effect as a factor in reported peptide benefits, and how social media amplifies it.
Risks and side effects
The safety of BPC-157 in people has not been established. A 2025 systematic review found no clinical safety data, and the US FDA says there is "insufficient clinical safety information to characterize the safety profile" of BPC-157.
What the US FDA's 2026 review found:
- Immune reactions: "As a peptide with 15 amino acids that is administered through a parenteral or nasal ROA, BPC-157 may pose a significant risk for immunogenicity." The FDA explains that immune reactions to peptide products can range from antibodies with no apparent effect to "life-threatening and catastrophic reactions". No study has formally tested BPC-157 products for this.
- Animal toxicity signals: in 28-day injection studies in rats and dogs, the FDA saw possible "clinically relevant safety signals", including changes in blood clotting times and liver-related markers (raised ALT, glucose and triglycerides). Longer studies were not available.
- No cancer-risk studies: the FDA identified no carcinogenicity studies of BPC-157.
Adverse event reports to the US FDA, searched through December 4, 2025:
| Report | What happened | FDA's comment |
|---|---|---|
| Injected BPC-157, used with injected thymosin | 9 days of redness and swelling at the injection site | The other product limits interpretation |
| Injected BPC-157 acetate, used for "injury/inflammation" | Shortness of breath leading to an emergency room visit | Too little information to interpret |
| Injected BPC-157 and TB-500 product labeled "research purposes only" | Darkening of the skin and gums, which came back when the product was used again | Likely related to the product, but it contained two peptides |
The FDA says it is unclear whether these events were caused by BPC-157.
Other reviewers agree on the uncertainty:
- A 2026 Sports Medicine review says "rigorous human safety data are scarce, and there is potential for serious harm to patients" for unapproved peptides including BPC-157.
- A 2026 Missouri Medicine review lists contamination, manufacturing impurities and inaccurate dosing among the potential risks of unregulated injectable peptides as a group.
- USADA says it is unknown whether any dose of BPC-157 can be used without harm.
Could BPC-157 affect tumour growth?
This is an open question. The US FDA found no carcinogenicity (cancer-risk) studies of BPC-157.
- The concern: a 2026 drug development review notes that BPC-157 is linked to VEGFR2 signalling and new blood vessel growth, and that blood vessel growth is a hallmark of cancer progression. The authors call this "a theoretical concern: BPC-157 could facilitate tumor vascularization in subjects with hidden or existing malignancy." They add that long-term cancer-risk data have not been produced.
- A wider warning: a 2026 Missouri Medicine review lists "pathological angiogenesis, carcinogenesis, cardiovascular stress" among the potential risks of unregulated drugs such as BPC-157, TB-500 and melanotan-II.
- The other view: the Zagreb research group that first described BPC-157 calls the tumour concern speculation, and reports anti-tumor potential in its own animal and lab studies.
Quality of products sold online
No regulator or peer-reviewed study testing the purity or contamination of BPC-157 products sold online was found. What the US FDA did find, when it reviewed BPC-157 as an ingredient for pharmacy compounding, raises quality concerns:
- Same name, different substances: BPC-157 is a common name, not an official drug name. The FDA "has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name", which it calls "a safety risk for patients".
- Thin certificates of analysis: the FDA found that most BPC-157 certificates of analysis it located "only contain purity testing results", with no impurity limits. The certificates submitted with the nominations had no results for specific impurities, clumped peptide (aggregates), microbial load or bacterial endotoxins. The FDA notes that an endotoxin test is critical for anything meant to be injected.
- Fragile molecule: the FDA says peptides like BPC-157 "can be extremely sensitive to product formulation, process, and environmental conditions", which can lead to clumping and breakdown.
- "Research use only" labels: Operation Supplement Safety says BPC-157 products may be labeled as research chemicals, "Not for human consumption" or "Research use only". It still calls BPC-157 an unapproved drug.
A 2026 review describes the core problem with unregulated peptides as people experimenting with "products of uncertain identity, purity, potency, sterility, and safety".
Is BPC-157 banned in sports?
Yes. The World Anti-Doping Agency (WADA) names BPC-157 in class S0, non-approved substances. This class covers substances with "no current approval by any governmental regulatory health authority for human therapeutic use" and is prohibited at all times, in and out of competition.
| WADA Prohibited List | BPC-157 status |
|---|---|
| 2022 | Named in class S0: "This class covers many different substances including but not limited to BPC-157." |
| 2026 | Still named in class S0, prohibited at all times |
| 2027 (in force from January 1, 2027) | Still named in class S0. The class definition now also lists "peptides" as an example of non-approved substances |
WADA's 2027 explanatory note warns that "Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health."
Other anti-doping and military bodies take the same line:
- USADA says a Therapeutic Use Exemption for BPC-157 is unlikely to be approved "because there are permitted alternatives available", although each application is considered case by case.
- Operation Supplement Safety, a US Department of Defense program, says BPC-157 "is not a dietary ingredient" and is on the DoD Prohibited Dietary Supplement Ingredients List.
- Testing: anti-doping researchers identified BPC 157 in confiscated vials and validated a urine test for it in 2017. A 2023 study reported a validated urine method for BPC-157 and five of its main breakdown products.
What is the US FDA's position on BPC-157?
The US FDA has not approved BPC-157, and in 2026 it proposed keeping it off the list of substances that US pharmacies may use for compounding.
| Date | What happened |
|---|---|
| Earlier (date not confirmed) | The US FDA had placed BPC-157 in category 2 of its compounding categories, for substances that "may present significant safety risks" |
| As of April 15, 2026 | According to a 2026 review, BPC-157 was removed from category 2 because the nominators withdrew their nominations |
| April 22, 2026 | The FDA's category 2 page lists BPC-157 under "Bulk drug substances nominated but withdrawn", described as substances "previously in category 2" |
| May 11, 2026 | Date of the FDA's evaluation of BPC-157 (free base) and BPC-157 acetate, made on its own initiative. It evaluated use in ulcerative colitis |
| July 23, 2026 | The FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 and was asked to vote on whether each form should be placed on the 503A bulks list. AJMC and DLA Piper (both July 31, 2026) reported that it voted 8 to 6, with 1 abstention, to recommend adding BPC-157 |
| As of October 7, 2026 | The FDA had posted no minutes and no decision on its meeting page, and BPC-157 was not on the 503A bulks list |
The FDA's proposal was clear: "FDA is proposing that BPC-157 (free base) NOT be included on the 503A Bulks List", and the same for BPC-157 acetate. Its reasons:
- BPC-157 is "not well characterized from a physiochemical perspective".
- There is "a lack of information on the safety profile and immunogenicity risks".
- The evidence is not enough to reach a conclusion on ulcerative colitis, and approved treatments for that disease already exist.
The committee's reported vote went the other way from the FDA's proposal. DLA Piper notes that "committee votes are non-binding recommendations, formal rulemaking is required before any substance is added to the list, and FDA is not obligated to follow the AdComm's recommendations." The FDA says it does not intend to issue a final determination until it has considered the committee's input. The FDA's category 2 page still repeats its safety concerns: compounded BPC-157 "may pose risk for immunogenicity", and the FDA "lacks sufficient information to know whether the drug would cause harm when administered to humans."
USADA's summary, for the US: "Currently, there is no legal basis to include BPC-157 in any compounded medication."
Legal status in the Philippines
The FDA Philippines registration status of BPC-157 is unverified: no record found in an FDA Philippines Verification Portal search on October 7, 2026. A search that finds no record is not an official FDA Philippines statement on the compound.
What was checked:
- On October 7, 2026, searches of the FDA Philippines website for "BPC-157", "bpc157" and "body protection compound" each returned no results.
- No Philippine source was found on whether BPC-157 needs a prescription, or on any legal way to obtain it here.
- The US FDA found no approved BPC-157 product in any country.
To check any product yourself, search the FDA Philippines verification portal at verification.fda.gov.ph. For how Philippine rules treat peptides in general, see are peptides legal in the Philippines.
FDA advisory history
No FDA Philippines advisory naming BPC-157 was found. On October 7, 2026, searches of the FDA Philippines website for "BPC-157" returned no results, and a search for "peptide" listed advisories on tirzepatide, collagen and cosmetic products, none naming BPC-157.
A missing advisory does not mean a product is registered or approved. FDA Philippines has issued advisories on some unregistered peptide products, such as two retatrutide products.
What to ask a doctor
If you are thinking about BPC-157, or have already used it, a licensed doctor can help. Questions you could bring:
- What approved treatments exist for my condition, and what does the evidence show for them?
- What should I watch for if I have already used BPC-157 or another unapproved injectable peptide?
- If I compete in sport, how does the WADA Prohibited List affect what I can take?
- How can I check whether a product is registered with FDA Philippines?
Frequently asked questions
Is BPC-157 legal in the Philippines?
Its FDA Philippines registration status is unverified: no record found in an FDA Philippines Verification Portal search on October 7, 2026. A search of the FDA Philippines website the same day found no page and no advisory naming BPC-157, and no Philippine source on a prescription route or any legal way to obtain it was found. A missing advisory does not mean a product is registered.
Is BPC-157 approved by the US FDA?
No. BPC-157 is not a component of any US FDA-approved drug, and in July 2026 the US FDA said there is no approved product containing BPC-157 in any country. Operation Supplement Safety, a US Department of Defense program, calls it an unapproved drug that cannot be legally prescribed or sold over the counter in the US.
Is BPC-157 banned in sports?
Yes. WADA names BPC-157 in class S0, non-approved substances, which is prohibited at all times, in and out of competition. It is named on the 2022 and 2026 lists and on the 2027 list that takes effect on January 1, 2027. USADA says a Therapeutic Use Exemption for it is unlikely to be approved.
Has BPC-157 been tested in humans?
Only in a handful of small studies. Three small pilot studies have full published results (16, 12 and 2 people), and two earlier studies were reported only as conference abstracts. None of the published pilots had a control group, and a 2026 review says no phase 2 trial has been completed.
What are the risks of BPC-157?
Its risks in people are largely unknown. The US FDA warns that, as an injected or nasal peptide, it may carry a significant risk of immune reactions, and its animal studies showed possible effects on blood clotting and liver markers. Products sold outside regulated channels add risks from impurities and unclear contents.
Can BPC-157 cause cancer?
This is not known. The US FDA found no cancer-risk (carcinogenicity) studies of BPC-157. A 2026 review raises a theoretical concern that, because it promotes new blood vessel growth in studies, it could help hidden or existing tumours develop a blood supply, while the research group that first described BPC-157 disputes this.
Is there an approved dose of BPC-157?
No. A 2026 review in the American Journal of Sports Medicine says the indications, dosing, frequency and duration of treatment remain unknown, and a 2026 drug development review says there is no validated dosing regimen. USADA says it is unknown whether any dose can be used without harm.
Where does BPC-157 come from?
It is made in a lab. Its 15 amino acid sequence matches part of a larger protein, called BPC, that researchers at the University of Zagreb reported isolating from gastric juice in 1993. USADA says BPC-157 products are synthetically produced.
What does "research use only" mean on BPC-157 products?
Operation Supplement Safety says products containing BPC-157 may be labeled as research chemicals, with statements such as "Research use only" or "Not for human consumption", and still calls BPC-157 an unapproved drug. One adverse event report reviewed by the US FDA involved a BPC-157 and TB-500 product labeled "research purposes only".
Can a doctor prescribe BPC-157 in the Philippines?
No source was found on any Philippine prescription route for BPC-157, and no record was found in an FDA Philippines Verification Portal search on October 7, 2026. The US FDA found no approved BPC-157 product in any country. A licensed doctor can discuss approved options for your condition.
Will the US allow BPC-157 in compounded medicines?
Not at present, according to USADA, which says there is currently no legal basis to include BPC-157 in any compounded medication. In 2026 the US FDA proposed that neither form of BPC-157 be added to its 503A bulks list. On July 23, 2026 its advisory committee was reported by AJMC and DLA Piper to have voted 8 to 6, with 1 abstention, to recommend adding BPC-157. Committee votes are non-binding, and no final FDA decision was found as of October 7, 2026.
Can BPC-157 be detected in a drug test?
Yes. Anti-doping researchers published a method in 2017 to detect BPC 157 in urine, and a 2023 study reported a validated method for BPC-157 and five of its main breakdown products in human urine.
Sources
- Sikiric et al., first description of the gastric juice peptide BPC, J Physiol Paris, 1993 (PMID 8298609)
- Sikiric et al., BPC 157 in trials for inflammatory bowel disease, Inflammopharmacology, 2006 (PMID 17186181)
- US FDA, briefing document on BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23 to 24, 2026
- US FDA, briefing document introduction, Pharmacy Compounding Advisory Committee, July 23 to 24, 2026
- US FDA, July 23 to 24, 2026 meeting of the Pharmacy Compounding Advisory Committee
- AJMC, FDA panel backs 6 peptides for compounding, July 31, 2026
- DLA Piper, FDA AdComm recommends adding six peptides to bulk list, July 31, 2026
- US FDA, bulk drug substances that may present significant safety risks (category 2)
- US FDA, bulk drug substances used in compounding under section 503A
- Vasireddi et al., systematic review of BPC-157, HSS Journal, 2025 (PMID 40756949)
- McGuire et al., narrative review of BPC-157 for musculoskeletal healing, 2025 (PMID 40789979)
- Yuan et al., review of BPC-157 in tissue repair and pain, 2026 (PMID 41898733)
- Gwyer et al., review of BPC 157 in soft tissue healing, Cell Tissue Res, 2019 (PMID 30915550)
- Mateescu et al., BPC-157 as an investigational peptide, Pharmaceutics, 2026 (PMID 42198317)
- Mateescu et al., full text via Europe PMC (PMC13210877)
- He et al., pharmacokinetics of BPC157 in rats and dogs, Front Pharmacol, 2022 (PMID 36588717)
- Yildirim et al., BPC 157 in human internal mammary artery tissue, J Clin Med, 2026 (PMID 42123221)
- Lee and Padgett, retrospective review of BPC 157 for knee pain, 2021 (PMID 34324435)
- Lee et al., pilot study in interstitial cystitis, 2024 (PMID 39325560)
- Lee and Burgess, intravenous safety pilot study, 2025 (PMID 40131143)
- PubMed records for the three human pilot studies (authors and journal)
- Mayfield et al., review of injectable peptides, American Journal of Sports Medicine, 2026 (PMID 41476424)
- Tewari et al., scoping review of peptide supplements in sports medicine, American Journal of Sports Medicine, 2026 (PMID 42578445)
- Mendias and Awan, review of approved and unapproved peptides, Sports Medicine, 2026 (PMID 41966639)
- Moiz et al., dangers of injectable peptides, Missouri Medicine, 2026 (PMID 42757290)
- Sikiric et al., BPC 157, angiogenesis and the NO system, Pharmaceuticals, 2025 (PMID 40573323)
- Hailu et al., unregulated peptide use, Cureus, 2026 (PMID 42437212)
- ClinicalTrials.gov, NCT02637284
- ClinicalTrials.gov, NCT07437547
- ClinicalTrials.gov, NCT07803250
- WADA, 2022 Prohibited List
- WADA, 2026 Prohibited List
- WADA, 2027 Prohibited List
- WADA, 2027 Prohibited List explanatory note
- USADA, BPC-157, what athletes should know
- Operation Supplement Safety (OPSS), BPC-157 as a prohibited peptide and unapproved drug
- Cox et al., detection of the confiscated peptides BPC 157 and MGF R23H, Drug Test Anal, 2017 (PMID 28035768)
- Tian et al., metabolic profile of BPC-157 for doping control, Molecules, 2023 (PMID 37959764)
- FDA Philippines, site search for BPC-157 (opened October 7, 2026)
- FDA Philippines Verification Portal, search for BPC-157, October 7, 2026
Related reading
This content is for education only and is not medical advice. Talk to a licensed doctor before starting any treatment.